CAR T-cell therapies are an ever-evolving area which calls for a high level of assay customization in clinical trials.
CAR T-cell therapy, a groundbreaking treatment for certain cancers, particularly hematological malignancies, has shown some success where traditional treatments have failed. However, its potential is still hindered by challenges such as variable patient responses and potential side effects. Overcoming these hurdles requires continuous research, as well as tailored clinical trials designed to address individual patient needs through customized biomarker panels, flow cytometry, molecular diagnostics (with qPCR or ddPCR), and advanced laboratory solutions.
Image Credit: Juan Gaertner/Shutterstock.com
Customizing flow cytometry and biomarker panels is critical to accurately monitoring and managing the effects of CAR T therapy. These customizations allow researchers to adapt protocols for diverse patient populations, ensuring that each trial is tailored to specific sample preparation and biomarker detection needs. Additionally, adjustments in assays and sample logistics help refine treatment protocols and ensure the reliability of trial data.
Given the complex nature of CAR T-cells, precise assay development and genomic monitoring techniques are essential to ensure the safe application of the therapy by detecting potential oncogenic risks. The development of robust, standardized assays and collaboration across global labs are crucial to overcoming these challenges, alongside maintaining stringent safety.
To learn how to overcome these challenges, read the full article now.
Download the full article to learn more
About Cerba Research
Cerba Research is a leading speciality laboratory services provider across all clinical development phases, to pharmaceutical, biotechnology, medical device, government, and public health organizations. It combines the deep scientific expertise of specialist services with the capacity and breadth of a global central laboratory network. Cerba Research develops innovative solutions to unique challenges in research and drives operational agility at scale for multiple focus areas, with world recognized expertise in virology, infectious diseases, oncology and cell and gene therapy. It is part of the Cerba HealthCare Group with 15,000 employees on five continents, driven to advance health diagnosis.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.